heparanase inhibitors (Beta Therapeutics/Jeremy Chrisp & Associates)

N/A

Report date: 2025/01/26 18:04:14
NME

Base Information

Drug Nameheparanase inhibitors (Beta Therapeutics/Jeremy Chrisp & Associates)
Drug Alias Nameheparanase inhibitors (Progen)sulfated oligosaccharides (Progen)
ClassificationSmall molecules > Carbohydrate > Oligosaccharide
Mechanisms of ActionHeparanase inhibitors
TargetsHeparanase
Therapy Area/IndicationsInflammationHyperlipidemiasDiabetes Mellitus, Type 2 +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTbg Diagnostics
China Registration ClassN/A

Develop Information

Active CompaniesJeremy Chrisp & AssociatesBeta Therapeutics Pty Ltd
Inactive CompaniesTbg Diagnostics
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Inactive IndicationsInflammationHyperlipidemiasCoronary Restenosis +[7] 

Other Information

ATC CodeN/A
Related LinksN/A